Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal Cancer

This study is testing an experimental combination of two immune cell therapies — CAR-DC (dendritic cell) and CAR-T cell therapy — both engineered to target a protein called Claudin18.2 found on certain cancer cells, in people with advanced colorectal cancer that has stopped responding to standard treatments. **You may be eligible if...** - You have been diagnosed with advanced colon or rectal cancer confirmed by biopsy, with at least one measurable tumor on imaging - Your tumor tests positive for the Claudin18.2 protein - You have already received standard chemotherapy regimens (fluoropyrimidine, irinotecan, and oxaliplatin) and your cancer has progressed - You are in reasonably good physical condition **You may NOT be eligible if...** - Your tumor does not express Claudin18.2 - You have not yet tried standard chemotherapy options - Your organs are not functioning well enough for this therapy - You have active infections, uncontrolled autoimmune diseases, or brain metastases Talk to your doctor to see if this trial is right for you.